Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | GPR3 | P46089 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.32 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | CASP6 | P55212 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | CRHBP | P24387 | 1/20 | 0.30 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.30 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.30 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4620642 | 0.76 | ATM (0.48) | ATMNPC1RAB9AKDM4EGPR3 | |
| SCHEMBL3535166 | 0.76 | ATM (0.48) | ATMNPC1RAB9AKDM4EGPR3 | |
| SCHEMBL8424490 | 0.76 | ATM (0.48) | ATMNPC1RAB9AKDM4EGPR3 | |
| SCHEMBL4559941 | 0.76 | ATM (0.48) | ATMNPC1RAB9AKDM4EGPR3 | |
| SCHEMBL9769436 | 0.76 | ATM (0.44) | ATMNPC1RAB9A | |
| SCHEMBL9769252 | 0.73 | ATM (0.45) | ATMNPC1RAB9AKDM4EGPR3 | |
| SCHEMBL5250885 | 0.73 | ATM (0.45) | ATMNPC1RAB9AKDM4EGPR3 | |
| SCHEMBL6081734 | 0.72 | ATM (0.44) | ATMNPC1RAB9A | |
| SCHEMBL8423013 | 0.72 | ATM (0.44) | ATMNPC1RAB9ACYP1A2CYP2A6 | |
| SCHEMBL4288878 | 0.72 | ATM (0.44) | ATMNPC1RAB9APDPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11939335-B2 | Substituted imidazo[1,2-a]quinazolines and imidazo [1,2-a]pyrido[4,3-e]pyrimidines as inhibitors of PARG | 858 THERAPEUTICS, INC. (US) | 2024-03-26 | — | — | US | disclosed |
| US-20230374022-A1 | INHIBITORS OF PARG | 858 THERAPEUTICS, INC. | 2023-11-23 | — | — | US | disclosed |
| EP-1644343-B1 | 5-SUBSTITUTED QUINAZOLINONE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2007-07-04 | — | — | EP | disclosed |
| US-20050124607-A1 | 5-Substituted quinazolinone compounds useful as alpha 1A/B adrenergic receptor antagonists | ROCHE PALO ALTO LLC | 2005-06-09 | — | — | US | disclosed |
| EP-0946095-A1 | FUNGICIDAL QUINAZOLINONES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1999-10-06 | — | — | EP | disclosed |
| WO-1998026664-A1 | FUNGICIDAL QUINAZOLINONES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1998-06-25 | — | — | WO | disclosed |
| EP-0411766-B1 | Substituted quinazolinones as angiotensin II antagonists | MERCK & CO INC (US) | 1994-01-19 | — | — | EP | disclosed |
| EP-0517357-A1 | Angiotensin II antagonists incorporating a substituted indole or dihydroindole | MERCK & CO. INC. (US) | 1992-12-09 | — | — | EP | disclosed |
| EP-0515535-A1 | ANGIOTENSIN II ANTAGONISTS INCORPORATING A SUBSTITUTED BENZYL ELEMENT | MERCK & CO. INC. (US) | 1992-12-02 | — | — | EP | disclosed |
| EP-0512870-A1 | Substituted quinazolinones bearing acidic functional groups as angiotensin II antagonists | MERCK & CO. INC. (US) | 1992-11-11 | — | — | EP | disclosed |
| EP-0512676-A1 | Angiotensin II antagonists incorporating a substituted benzyl element | MERCK & CO. INC. (US) | 1992-11-11 | — | — | EP | disclosed |
| EP-0510812-A1 | Angiotensin II antagonists incorporating a substituted thiophene or furan | MERCK & CO. INC. (US) | 1992-10-28 | — | — | EP | disclosed |
| WO-1991012001-A1 | ANGIOTENSIN II ANTAGONISTS INCORPORATING A SUBSTITUTED BENZYL ELEMENT | MERCK & CO., INC. (US) | 1991-08-22 | — | — | WO | disclosed |
| EP-0411766-A1 | Substituted quinazolinones as angiotensin II antagonists | MERCK & CO. INC. (US) | 1991-02-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230374022-A1 | INHIBITORS OF PARG | PARG, PLG, SERPINB1 | ATM 3147/4885NPC1 941/4885RAB9A 2037/4885 |
| US-20050124607-A1 | 5-Substituted quinazolinone compounds useful as alpha 1A/B adrenergic receptor antagonists | ADRB1, ADRA1B, ADRB2 | ATM 4228/4885NPC1 1690/4885RAB9A 792/4885 |
| US-11939335-B2 | Substituted imidazo[1,2-a]quinazolines and imidazo [1,2-a]pyrido[4,3-e]pyrimidines as inhibitors of PARG | PARG, PTGIS, PLG | ATM 4324/4885NPC1 1470/4885RAB9A 1437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.